Supplementary immunotherapeutics to be used after lung...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 45/00 (2006.01) A61K 31/00 (2006.01) A61K 31/198 (2006.01) A61P 35/00 (2006.01) A61P 43/00 (2006.01)

Patent

CA 2445314

Recurrence-free survival time-extending agents for patients with lung squamous carcinoma at the pathologic histological stage I which contain aminopeptidase inhibitors such as ubenimex as the active ingredient; or survival time- extending agents, in particular, recurrence-free survival time-extending agents for patients with the same disease at the pathologic histological stage IB after lung cancer removal.

L'invention concerne des agents permettant d'accroître le temps de survie et d'empêcher une rechute chez des patients atteints d'un carcinome squameux pulmonaire au stade pathologique histologique I. Ces agents contiennent des inhibiteurs des aminopeptidases tels que de l'Ubenimex comme principe actif. L'invention concerne en outre des agents d'accroissement du temps de survie, en particulier des agents permettant d'accroître le temps de survie et d'empêcher une rechute chez des patients atteints de la même maladie au stade pathologique histologique IB et ayant subi une ablation pulmonaire liée audit cancer.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Supplementary immunotherapeutics to be used after lung... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Supplementary immunotherapeutics to be used after lung..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Supplementary immunotherapeutics to be used after lung... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1592314

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.